Metabolic Markers to Track on a GLP-1: A1c, BP, Lipids

The scale is the metric everyone watches on a GLP-1, but it is not the one that best captures why these drugs matter for health. Semaglutide and tirzepatide were studied (and are increasingly used) for their effects on the numbers that predict long-term risk: blood sugar, blood pressure, and blood lipids. If you want to know whether a GLP-1 is doing its job, the blood-work picture is where a lot of the answer lives.

This guide covers the metabolic markers worth tracking, what commonly cited healthy targets look like, and what the trials found when they measured these numbers. Pair it with a running log of your own results. Our GLP-1 progress tracker is built for exactly this kind of beyond-the-scale monitoring. One firm caveat up front: this is educational, not medical advice. Which labs to order, how often, and what your personal targets should be are decisions for your clinician.

Why markers beat the scale

Weight is a proxy. What clinicians and long-term outcome trials care about are the downstream measures that fat loss tends to improve: glycemic control, arterial pressure, and the lipid particles that drive cardiovascular disease. Two people can lose the same number of pounds and see different changes in these markers, which is why tracking them, not just body weight, tells you more about the health return on the medication.

GLP-1s also move some of these numbers partly independently of weight, through effects on appetite, insulin secretion, and inflammation. So even in a month where the scale is flat, your blood work can show the drug is still working.

A GLP-1’s benefit shows up in blood work, not just on the scale: A1c, blood pressure, and lipids often improve alongside weight.

Marker 1: A1c (glycemic control)

Hemoglobin A1c reflects your average blood glucose over roughly the prior three months, which makes it the standard measure of glycemic control. Widely used reference bands are: below 5.7% is normal, 5.7-6.4% is prediabetes, and 6.5% or above is in the diabetes range. For many people with diabetes, a commonly cited treatment goal is an A1c below 7%, though the right target is individualized and should be set with a clinician.

GLP-1s were glucose-lowering drugs before they were weight-loss drugs, so improvement here is expected. In the STEP 1 trial of people with overweight or obesity (most without diabetes), semaglutide improved A1c relative to placebo among its secondary outcomes. If you started with prediabetes or type 2 diabetes, A1c is one of the most important markers to watch: a downward trend is a direct readout of the drug’s metabolic effect.

Marker 2: Blood pressure

Blood pressure is cheap to measure and strongly tied to cardiovascular risk, which makes it one of the highest-value things to track at home and in the clinic. The 2025 AHA/ACC hypertension guidance recommends a target of under 130/80 mmHg for most adults, including adults with diabetes, with individualized (less strict) targets for older or frail patients.

This is an area where GLP-1s show a clear, measurable effect. In STEP 1, semaglutide lowered systolic blood pressure by about 5 mmHg more than placebo (roughly a 6 mmHg drop on the drug versus about 1 mmHg on placebo). Tirzepatide trials show blood-pressure reductions in a similar or larger range, tracking with the greater weight loss. A drop of a few mmHg sounds modest but is meaningful at the population level for stroke and heart-disease risk. Our companion piece on what the trials found for GLP-1s and blood pressure goes deeper on the mechanism and the numbers.

Marker 3: Lipids

A standard lipid panel reports total cholesterol, LDL (“bad”) cholesterol, HDL (“good”) cholesterol, and triglycerides. Commonly cited reference points from patient-facing guidance include total cholesterol under 200 mg/dL, HDL above 60 mg/dL as protective, and LDL that is lower being better, with 190 mg/dL or higher considered clearly too high. The optimal LDL target is risk-dependent: people with diabetes or existing cardiovascular disease are usually steered toward substantially lower LDL goals than the general population, which is a conversation to have with your clinician rather than a single universal number.

GLP-1s tend to nudge lipids in a favorable direction as weight comes down — most consistently lower triglycerides, with smaller improvements in the cholesterol fractions. The effects are generally more modest than what a dedicated lipid drug (like a statin) delivers, so a GLP-1 complements rather than replaces lipid-specific treatment. For the fuller picture, see GLP-1s and cholesterol: the secondary metabolic effects.

Marker 4: Inflammation (hs-CRP)

High-sensitivity C-reactive protein (hs-CRP) is a marker of systemic inflammation and an independent cardiovascular risk signal. It is not on every routine panel, but it is one of the more striking GLP-1 findings: a pooled analysis of STEP 1, 2, and 3 found semaglutide reduced CRP by roughly 39-48% versus placebo across the trials (about -44% in STEP 1). That is a large anti-inflammatory effect, moving in parallel with weight loss.

A sensible tracking table

Here is a practical view of the markers above. Frequencies are general orientation only — your clinician sets the actual schedule based on your history.

Marker	Common reference point	Typical monitoring cadence
A1c	< 7% goal for many with diabetes; < 5.7% normal	Every 3-6 months
Blood pressure	< 130/80 mmHg (most adults)	Home readings; each visit
Lipid panel	TC < 200; LDL lower is better; TG lower	Periodically per risk
hs-CRP	Lower is better	As ordered by clinician
Waist circumference	See the waist vs weight guide	Alongside weigh-ins

Notice weight isn’t the only body measure worth logging — waist circumference often tracks visceral-fat loss better than the scale, which we cover in waist circumference vs weight on a GLP-1.

The takeaway

A GLP-1’s real work shows up in your metabolic markers: A1c, blood pressure, lipids, and inflammation all tend to improve alongside — and sometimes ahead of — weight. Know the common reference targets (A1c under 7% for many with diabetes, blood pressure under 130/80, lower LDL and triglycerides), and remember that the trials back real effects here: a roughly 5 mmHg systolic drop and a ~44% CRP reduction in STEP 1 are not rounding errors. Log these numbers over time with our GLP-1 progress tracker and review them with your clinician, who decides which labs to run, how often, and what your personal targets are. This article is educational and not a substitute for that care.

Sources

• STEP 1 once-weekly semaglutide (WikiJournalClub)
• Effects of semaglutide 2.4 mg on C-reactive protein, STEP 1/2/3 (PMC)
• 2025 AHA/ACC hypertension guidelines and diabetes (PMC)
• Hemoglobin A1C Test (MedlinePlus)
• Understanding lipid panel results (MedlinePlus)
• ADA Standards of Care in Diabetes (2025) — A1c and cardiovascular risk targets (guideline; specific URL not linked)